United States Patent 4,432,963: Claim Scope, Expiration, and Patent Landscape for Technetium-99m Methanehydroxydiphosphonate

United States Patent 4,432,963 covers water-soluble methanehydroxydiphosphonate compositions containing selected divalent or trivalent metals and technetium-99m. Claims 1-4 cover metal methanehydroxydiphosphonates. Claims 5-9 cover technetium-99m compositions, including technetium-99m methanehydroxydiphosphonate and mixed technetium-metal compositions.

The patent is no longer an enforceable U.S. patent. Its ordinary pre-1995 term was 17 years from grant, placing expiration in 2001. The claims did not create a current barrier to generic or competing radiopharmaceutical products. Their commercial significance was concentrated in the development of technetium-99m bone-imaging agents and associated radiopharmaceutical kits.

What does U.S. Patent 4,432,963 cover?

The patent claims nine compositions of matter:

Claim	Claimed subject matter	Primary scope
1	Water-soluble stannous methanehydroxydiphosphonate	Sn(II)-MHDP composition
2	Water-soluble ferrous methanehydroxydiphosphonate	Fe(II)-MHDP composition
3	Water-soluble chromous methanehydroxydiphosphonate	Cr(II)-MHDP composition
4	Water-soluble titanous methanehydroxydiphosphonate	Titanium-MHDP composition
5	Water-soluble technetium-99m methanehydroxydiphosphonate	Tc-99m-MHDP composition
6	Water-soluble technetium-99m methanehydroxydiphosphonate-tin	Tc-99m-MHDP-Sn composition
7	Water-soluble technetium-99m methanehydroxydiphosphonate-iron	Tc-99m-MHDP-Fe composition
8	Water-soluble technetium-99m methanehydroxydiphosphonate-chromium	Tc-99m-MHDP-Cr composition
9	Water-soluble technetium-99m methanehydroxydiphosphonate-titanium	Tc-99m-MHDP-Ti composition

The core technical concept is a water-soluble diphosphonate coordination composition capable of incorporating technetium-99m. Methanehydroxydiphosphonate is commonly associated with hydroxymethylene diphosphonate and the radiopharmaceutical category later marketed as technetium Tc-99m oxidronate or Tc-99m HDP.

What is the claim construction of methanehydroxydiphosphonate?

The claims use the older chemical name “methanehydroxydiphosphonate.” The compound is generally represented as hydroxymethylene diphosphonic acid or hydroxymethane diphosphonate. The naming distinction matters because patent scope depends on chemical identity, not solely on the commercial name used for a finished kit.

The claims do not state:

A specific counterion.
A defined metal-to-ligand ratio.
A crystal form.
A hydration state.
A pH range.
A concentration.
A stabilizer.
A reducing agent.
A sterile vial.
A generator system.
A dosage.
A diagnostic imaging method.
A manufacturing process.

The phrase “water-soluble” is a material limitation. A composition that is insoluble, materially precipitated, or present only as an insoluble suspension would have a stronger non-infringement position under the literal language. The term also creates potential claim-construction issues because solubility depends on pH, ionic strength, concentration, counterions, and measurement conditions.

Claims 1-4 use oxidation-state terminology:

Stannous means tin in the +2 oxidation state.
Ferrous means iron in the +2 oxidation state.
Chromous means chromium in the +2 oxidation state.
Titanous generally refers to titanium in the +3 oxidation state.

A product containing stannic tin, ferric iron, chromic chromium, or titanium in a different oxidation state would not literally meet the corresponding claim unless the claimed composition also contained the specified oxidation state.

How broad are claims 1 through 4?

Claims 1-4 are narrow species claims directed to four metal-MHDP compositions. They are not broad claims to every metal diphosphonate or every technetium-labeled phosphonate.

Claim 1: stannous methanehydroxydiphosphonate

Claim 1 covers a water-soluble composition containing MHDP and stannous tin. In the technetium-99m field, stannous compounds commonly function as reducing components that facilitate technetium labeling. The claim is potentially relevant to a kit in which the tin-MHDP complex is present before addition of technetium-99m pertechnetate.

The claim does not expressly require technetium-99m. A tin-MHDP composition could therefore fall within claim 1 even if it was sold as a precursor or kit component without radioactive technetium.

Claim 2: ferrous methanehydroxydiphosphonate

Claim 2 covers the corresponding iron(II) composition. It is structurally separate from claim 1 and does not cover all iron-MHDP species regardless of oxidation state.

Claim 3: chromous methanehydroxydiphosphonate

Claim 3 covers chromium(II)-MHDP. This is a narrower and less commercially conventional species than tin-based reducing compositions. The claim’s commercial importance would depend on whether a marketed product actually used chromium in the claimed oxidation state and coordination environment.

Claim 4: titanous methanehydroxydiphosphonate

Claim 4 covers a titanium-MHDP composition using the historical term “titanous.” Chemical characterization would be important in any infringement analysis because titanium oxidation state and coordination chemistry can change during preparation, storage, or technetium labeling.

What do claims 5 through 9 cover?

Claims 5-9 are the patent’s principal radiopharmaceutical claims.

Claim 5: technetium-99m methanehydroxydiphosphonate

Claim 5 covers a water-soluble composition of technetium-99m and MHDP. It does not require tin, iron, chromium, or titanium. The claim therefore reaches a binary technetium-MHDP composition, subject to the water-solubility limitation.

A finished product could potentially fall within claim 5 even if its commercial formulation included excipients, buffers, preservatives, or other inactive components. Those additional ingredients would not necessarily avoid the claim if the claimed Tc-99m-MHDP composition remained present.

Claims 6-9: mixed technetium-metal compositions

Claims 6-9 cover technetium-99m-MHDP compositions containing the specified metal:

Claim 6: tin.
Claim 7: iron.
Claim 8: chromium.
Claim 9: titanium.

The claim language does not clearly define whether the metal must be directly coordinated to the same MHDP ligand, must be present in a discrete ternary molecular species, or may be present as part of a mixture of related complexes. That issue would depend on the patent specification, prosecution history, analytical evidence, and the applicable claim-construction record.

For a modern infringement analysis, product characterization would likely include radiochemical purity testing, elemental analysis, oxidation-state analysis, chromatography, spectroscopy, and assessment of whether the product contains a discrete ternary complex or only a mixture of technetium and metal-containing components.

When did U.S. Patent 4,432,963 expire?

Patent 4,432,963 was granted in the pre-1995 U.S. patent-term regime. Its ordinary term was 17 years from the grant date, subject to any applicable terminal disclaimer, disclaimer, or earlier lapse.

The patent therefore expired in 2001. The patent cannot presently be asserted to block manufacture, sale, use, importation, or development of the claimed compositions in the United States.

Patent	Technology	Grant era	Ordinary U.S. term	Status
US 4,432,963	Tc-99m-MHDP and metal-MHDP compositions	1984	17 years from grant	Expired in 2001

Patent expiration eliminates current infringement risk under this patent. It does not eliminate possible risk from later patents directed to formulations, kits, manufacturing processes, delivery systems, or separate radiopharmaceutical compositions.

Did the patent claim a manufacturing process or a diagnostic method?

No. The supplied claims are composition claims only.

The patent does not claim:

Preparation of methanehydroxydiphosphonate.
Reduction of pertechnetate with stannous ion.
Reconstitution of a radiopharmaceutical kit.
Administration to a patient.
Bone imaging.
Detection of skeletal lesions.
Quality-control testing.
Use of a particular generator or radionuclide production route.

This distinction limits the patent’s scope. A later patent could have covered a preparation method or kit even if it used the same active Tc-99m-MHDP composition. Conversely, a later process patent could be relevant to commercial manufacture without changing the expired status of the composition claims in Patent 4,432,963.

What was the likely commercial relevance of the claims?

The claims align with the development of technetium-99m bone-seeking radiopharmaceuticals. Diphosphonates bind to hydroxyapatite in bone and permit skeletal imaging after labeling with technetium-99m.

Commercial products in this field have included Tc-99m diphosphonate and Tc-99m oxidronate or HDP kits supplied as nonradioactive ingredients for reconstitution with technetium-99m pertechnetate. Product names and active ingredient descriptions have varied by manufacturer and jurisdiction.

The patent’s strongest commercial relevance was likely claim 5 and the tin-related claims. Tin was widely used in technetium radiopharmaceutical chemistry as a reducing agent. The chromium and titanium species appear more specialized and would require product-specific evidence before being treated as commercially important.

What is the Orange Book status of U.S. Patent 4,432,963?

Patent 4,432,963 should not be treated as a current Orange Book barrier.

The FDA Orange Book lists patents and exclusivity information for approved drug products, but an old composition patent does not remain a live regulatory barrier after expiration. Radiopharmaceutical kits also may appear under different regulatory and product-listing structures depending on the product, dosage form, approval history, and FDA database record.

The relevant regulatory distinctions are:

Issue	Assessment
Current patent term	Expired
Current Paragraph IV exposure under this patent	None
Current Orange Book blocking effect	None
Possible FDA approval pathway	NDA or applicable abbreviated or 505(b)(2)-type pathway, depending on product
Product-specific patents	Must be reviewed separately
Biosimilar pathway	Not applicable

Are Paragraph IV challenges relevant to this patent?

No current Paragraph IV challenge is commercially relevant to Patent 4,432,963 because the patent expired in 2001.

A Paragraph IV certification is directed to an unexpired patent listed for an approved drug product. A generic applicant could not obtain a meaningful litigation advantage by challenging an expired patent. The applicant would instead proceed against any unexpired listed patents or rely on a certification that relevant patents had expired or were otherwise not applicable.

The original patent could have influenced historical competition, but it no longer supports an infringement suit or a 30-month stay under the Hatch-Waxman framework.

Does biosimilar risk apply to technetium-99m methanehydroxydiphosphonate?

No. Biosimilar law applies to biological products. Technetium-99m methanehydroxydiphosphonate is a chemically defined small-molecule radiopharmaceutical, not a biologic.

The relevant competitive pathways are:

Generic or abbreviated-drug competition.
505(b)(2) applications.
NDA-based competition.
Compounded or institutional radiopharmaceutical supply, where legally permitted.
Hospital and radiopharmacy purchasing competition.

The regulatory classification of a specific product depends on its formulation, labeling, manufacturing process, approval history, and the FDA’s treatment of the product category.

How strong is the patent estate for Tc-99m methanehydroxydiphosphonate?

The estate represented by Patent 4,432,963 is no longer legally strong because it is expired. Historically, its strengths were:

Composition claims rather than only process claims.
Direct coverage of the Tc-99m-MHDP active composition.
Separate coverage of metal-containing variants.
Coverage that did not depend on a particular dose, kit, or imaging indication.

Its limitations were equally important:

No method-of-use claims.
No kit claims.
No formulation-specific claims.
No manufacturing claims.
No explicit concentration or stoichiometric limitations.
No coverage of all diphosphonates or all technetium radiopharmaceuticals.
No current enforceability after expiration.

The patent would have been most vulnerable to a design-around using a different diphosphonate ligand, a different reducing system, a non-MHDP technetium complex, or a formulation outside the water-soluble composition described in the claims.

What later patent risks could remain after expiration?

Expiration of Patent 4,432,963 does not establish freedom to operate for every Tc-99m bone-imaging product. A current review would need to distinguish the expired foundational composition claims from later patent families covering:

Stable kit formulations.
Lyophilized compositions.
Specific excipient systems.
Improved radiochemical purity.
Shelf-life extension.
Sterile manufacturing.
Container-closure systems.
Generator-elution and reconstitution procedures.
Automated radiopharmacy systems.
Alternative diphosphonate ligands.
Labeling methods.
Combination diagnostic agents.
New imaging indications.

For a generic launch, the principal remaining risks would likely be regulatory and commercial rather than Patent 4,432,963 itself. These include FDA approval requirements, radioactive-material licensing, current manufacturing standards, supply of technetium-99m, validation of radiochemical purity, and hospital purchasing contracts.

Which companies challenged or licensed Patent 4,432,963?

The supplied claim set does not establish a licensing agreement, assignment history, litigation outcome, or Paragraph IV challenge. No such event should be inferred from the claims alone.

A complete ownership and litigation review would require the USPTO assignment database, the patent’s prosecution history, federal court dockets, FDA product records, and commercial licensing disclosures. The patent number itself does not establish that any particular manufacturer licensed the technology or that any named company challenged it.

What is the geographic coverage of the patent?

U.S. Patent 4,432,963 provided rights only in the United States. It did not directly control:

European manufacture or sale.
Canadian products.
Japanese products.
Australian products.
Products made outside the United States and never imported into the United States.

Foreign counterparts, if any, would require separate review by country. A U.S. patent’s expiration has no automatic legal effect on foreign patent rights, although patents filed from the same priority disclosure may have expired on similar timelines under local law.

What generic launch scenarios exist today?

Because Patent 4,432,963 expired, three practical launch scenarios exist:

Scenario	Patent position	Main business issue
Same Tc-99m-MHDP active composition	No barrier from US 4,432,963	FDA pathway and manufacturing validation
Tc-99m-MHDP with a new kit formulation	No barrier from the expired composition patent	Later formulation patents and regulatory approval
Alternative Tc-99m diphosphonate	Outside the literal MHDP claims	Separate patent and clinical/regulatory review

A company developing a current product should treat the patent as historical prior art and a potential disclosure source, not as an active exclusivity right.

Key Takeaways

U.S. Patent 4,432,963 claims water-soluble methanehydroxydiphosphonate compositions containing tin, iron, chromium, titanium, or technetium-99m.
Claims 5-9 are the central radiopharmaceutical claims.
The patent claims compositions, not imaging methods, manufacturing processes, or commercial kits.
“Water-soluble” and the specified metal oxidation states are important limitations.
The patent expired in 2001 under the pre-1995 17-year term regime.
It presents no current Paragraph IV, Orange Book, or generic-launch barrier.
Biosimilar analysis is irrelevant because Tc-99m-MHDP is a chemically defined small molecule.
Current freedom-to-operate risk would arise from later formulation, kit, process, manufacturing, or product-specific patents.
The claims alone do not establish licensing, assignment, litigation, or commercial adoption by any particular company.

FAQs About U.S. Patent 4,432,963

Is technetium-99m methanehydroxydiphosphonate the same as technetium-99m oxidronate?

They are generally treated as the same or closely corresponding chemical and commercial category, with terminology depending on the product label and chemical nomenclature used.

Can a company manufacture a Tc-99m-MHDP kit without infringing Patent 4,432,963?

Yes, this expired patent cannot presently support an infringement claim. The company must still evaluate later patents, FDA requirements, radioactive-material controls, and manufacturing regulations.

Did Patent 4,432,963 cover technetium-99m MDP products?

Not necessarily. Methanehydroxydiphosphonate and methylene diphosphonate are distinct ligands. Product identity must be established chemically rather than inferred from the general category of technetium bone agents.

Could claim 5 cover a formulation containing buffers and reducing agents?

Potentially, if the formulation contains the claimed water-soluble technetium-99m methanehydroxydiphosphonate composition. Added excipients do not automatically avoid a composition claim.

Does expiration of Patent 4,432,963 invalidate later patents on Tc-99m radiopharmaceutical kits?

No. Later patents are evaluated independently. The expiration removes only the rights provided by Patent 4,432,963 and any properly linked patent rights that expired with it.

References

United States Patent and Trademark Office. (1984). U.S. Patent No. 4,432,963. Washington, DC: U.S. Department of Commerce.
U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. Center for Drug Evaluation and Research.
United States Congress. (2011). 35 U.S.C. § 154: Contents and term of patent; provisional rights.
United States Congress. (2011). 21 U.S.C. § 355: New drugs.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	4935979	⤷ Start Trial
Australia	530496	⤷ Start Trial
Canada	1143285	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 4,432,963

Summary for Patent: 4,432,963